




Searching News Database: Renal Disease
HSMN NewsFeed - 27 Jun 2024
VenoStent Completes $20 Million Series A with $4 Million Investment from Norwest Venture Partners
VenoStent Completes $20 Million Series A with $4 Million Investment from Norwest Venture Partners
HSMN NewsFeed - 23 Aug 2023
Fresenius Medical Care Announces FDA Clearance of Versi(R)HD with GuideMe Software
Fresenius Medical Care Announces FDA Clearance of Versi(R)HD with GuideMe Software
HSMN NewsFeed - 18 Aug 2023
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy
HSMN NewsFeed - 23 Jun 2023
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
HSMN NewsFeed - 24 Feb 2022
Artio Medical Welcomes New R&D Leaders and Accelerates Development of Amplifi(TM) Vein Dilation System
Artio Medical Welcomes New R&D Leaders and Accelerates Development of Amplifi(TM) Vein Dilation System
HSMN NewsFeed - 30 Oct 2020
Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis
Minimally Invasive Ellipsys System Creates Fused, Permanent Vascular Access for Dialysis
HSMN NewsFeed - 11 Oct 2019
Transplant Genomics, Inc. Confirms TruGraf(R) Will Receive Medicare Coverage Effective November 25, 2019
Transplant Genomics, Inc. Confirms TruGraf(R) Will Receive Medicare Coverage Effective November 25, 2019
HSMN NewsFeed - 11 Feb 2019
Fresenius Medical Care North America Launches 2008T BlueStar(TM) Hemodialysis Machine Across the U.S.
Fresenius Medical Care North America Launches 2008T BlueStar(TM) Hemodialysis Machine Across the U.S.
HSMN NewsFeed - 3 Dec 2018
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
Variant Pharmaceuticals Secures $10 Million in Financing from Korean Company, Incon Co., Ltd.
HSMN NewsFeed - 9 Jul 2018
BD Acquires TVA Medical to Advance Leadership in Solutions for Chronic Kidney Disease
BD Acquires TVA Medical to Advance Leadership in Solutions for Chronic Kidney Disease
HSMN NewsFeed - 11 Jan 2018
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
Resverlogix Receives FDA Protocol Acceptance for the Ongoing Phase 3 BETonMACE Trial
HSMN NewsFeed - 10 Jan 2018
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
BYDUREON(R) BCise(TM) Injectable Medicine Now Available In The US For Patients With Type-2 Diabetes
HSMN NewsFeed - 28 Aug 2017
NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage(R) System One(TM)
NxStage Medical Announces FDA Clearance for Solo Home Hemodialysis Using NxStage(R) System One(TM)
HSMN NewsFeed - 15 Aug 2017
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
Pharmalink Strengthens Its Management Team. Appoints New Chief Financial Officer and Head of Communications
HSMN NewsFeed - 12 May 2017
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
Ardelyx Reports Successful Phase 3 T3MPO-1 Trial of Tenapanor in Patients with IBS-C
HSMN NewsFeed - 17 Feb 2017
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
LYNPARZA(TM) (olaparib) Meets Primary Endpoint in Phase III Trial in BRCA-Mutated Metastatic Breast Cancer
HSMN NewsFeed - 29 Nov 2016
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
OxThera Raises EUR 32 Million to Complete Development of Oxabact(R) for Treatment of Primary Hyperoxaluria
HSMN NewsFeed - 28 Nov 2016
Conditional Approval from the European Commission to Treat Multiple Myeloma
Conditional Approval from the European Commission to Treat Multiple Myeloma
HSMN NewsFeed - 24 Oct 2016
Baxter Launches HDx Therapy Enabled by THERANOVA to Provide High Performance Hemodialysis Treatments
Baxter Launches HDx Therapy Enabled by THERANOVA to Provide High Performance Hemodialysis Treatments
HSMN NewsFeed - 10 Oct 2016
Teleflex Receives FDA Clearance for ARROW(R)JACC with Chlorag+ard(R) Technology and Tunneler
Teleflex Receives FDA Clearance for ARROW(R)JACC with Chlorag+ard(R) Technology and Tunneler
HSMN NewsFeed - 7 Jun 2016
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
Sanifit Appoints Preston S. Klassen MD, MHS as Chief Medical Officer and Announces new US Subsidiary
HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
HSMN NewsFeed - 9 May 2016
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
Theravance Biopharma Announces FDA Approval of Expanded Label for VIBATIV(R) (telavancin)
HSMN NewsFeed - 16 Feb 2016
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
VIVLODEX(TM) Now Available in U.S. Pharmacies for the Management of Osteoarthritis Pain
HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
HSMN NewsFeed - 5 Feb 2016
TVA Medical Receives Additional Reimbursement in Germany for the everlinQ(TM) endoAVF System
TVA Medical Receives Additional Reimbursement in Germany for the everlinQ(TM) endoAVF System
HSMN NewsFeed - 4 Feb 2015
Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer
Concert Pharmaceuticals Announces Appointment of James V. Cassella as Chief Development Officer
HSMN NewsFeed - 29 May 2014
Flow Forward Announces Spinout from Novita, to Focus on Development of Lead Product, the AFE System(TM)
Flow Forward Announces Spinout from Novita, to Focus on Development of Lead Product, the AFE System(TM)
HSMN NewsFeed - 15 May 2014
Sorbent Therapeutics Closes First Tranche Of $15 Million Series D Financing
Sorbent Therapeutics Closes First Tranche Of $15 Million Series D Financing
HSMN NewsFeed - 29 Apr 2014
CryoLife Receives FDA 510(k) Clearance for PerClot(R) Topical Hemostatic Powder in the U.S.
CryoLife Receives FDA 510(k) Clearance for PerClot(R) Topical Hemostatic Powder in the U.S.
HSMN NewsFeed - 8 Apr 2014
Fresenius Medical Care Renal Therapies Group Announces Chief Medical Officer to Retire
Fresenius Medical Care Renal Therapies Group Announces Chief Medical Officer to Retire
HSMN NewsFeed - 27 Mar 2014
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies
Baxter Announces Plans to Create Two Separate Leading Global Healthcare Companies
HSMN NewsFeed - 24 Mar 2014
FDA Grants Diazyme 510(k) Clearance to Market Its Vitamin D Assay for Clinical Chemistry Analyzers
FDA Grants Diazyme 510(k) Clearance to Market Its Vitamin D Assay for Clinical Chemistry Analyzers
HSMN NewsFeed - 17 Mar 2014
BioCardia(R) Receives CE Mark for Morph AccessPro(TM) Steerable Introducer
BioCardia(R) Receives CE Mark for Morph AccessPro(TM) Steerable Introducer
HSMN NewsFeed - 23 Jan 2014
Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
Concert Pharmaceuticals Announces the Appointment of Ryan Daws as Chief Financial Officer
HSMN NewsFeed - 21 Jan 2014
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
HSMN NewsFeed - 7 Jan 2014
Barostim Therapy(TM) Projected to be Cost-Effective in Treating Resistant Hypertension
Barostim Therapy(TM) Projected to be Cost-Effective in Treating Resistant Hypertension
HSMN NewsFeed - 16 Oct 2013
Akebia Appoints Jason A. Amello as Senior Vice President, Chief Financial Officer and Treasurer
Akebia Appoints Jason A. Amello as Senior Vice President, Chief Financial Officer and Treasurer
HSMN NewsFeed - 28 Aug 2013
Akebia Appoints Renal Industry Veteran John P. Butler as President and CEO
Akebia Appoints Renal Industry Veteran John P. Butler as President and CEO
HSMN NewsFeed - 24 Jul 2013
FDA Grants Diazyme 510(k) Clearance to Market Its Myoglobin Assay for Clinical Chemistry Analyzers
FDA Grants Diazyme 510(k) Clearance to Market Its Myoglobin Assay for Clinical Chemistry Analyzers
HSMN NewsFeed - 13 Jun 2013
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
PRISM Pharma Closes $15 million Series C Financing to Advance PRI-724 into Non-oncology Indications
HSMN NewsFeed - 10 Jun 2013
TVA Medical Raises $9.5 Million to Advance Minimally Invasive Therapy for End-Stage Renal Disease
TVA Medical Raises $9.5 Million to Advance Minimally Invasive Therapy for End-Stage Renal Disease
HSMN NewsFeed - 30 Apr 2013
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
NxStage Announces FDA Clearance for New High Flow Capabilities with NxStage System One
HSMN NewsFeed - 13 Mar 2013
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs
HSMN NewsFeed - 25 Feb 2013
NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
NxStage Announces CE Mark Approval, First Clinical Use of its Single Needle for Dialysis Patients
HSMN NewsFeed - 21 Feb 2013
NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
NxStage Announces CE Mark Approval for New High Flow Capabilities with System One
HSMN NewsFeed - 15 Jan 2013
Rex Medical Cleaner15 Rotational Thrombectomy System Receives 510(k) Clearance
Rex Medical Cleaner15 Rotational Thrombectomy System Receives 510(k) Clearance
HSMN NewsFeed - 3 May 2012
CorMedix Strengthens Management Team with Addition of Randy Milby as Chief Operating Officer
CorMedix Strengthens Management Team with Addition of Randy Milby as Chief Operating Officer
HSMN NewsFeed - 23 Apr 2012
Nephros Appoints John C. Houghton as President and Chief Executive Officer
Nephros Appoints John C. Houghton as President and Chief Executive Officer
HSMN NewsFeed - 28 Nov 2011
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
CorMedix Appoints Pharmaceutical Veteran, Matthew Duffy to Board of Directors
HSMN NewsFeed - 30 Jun 2011
Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million
Sorbent Therapeutics Completes $36 Million Series B Financing for Net of $53 Million
HSMN NewsFeed - 22 Feb 2011
Gore Receives CE Mark for GORE(R) PROPATEN(R) Vascular Graft for Hemodialysis Access
Gore Receives CE Mark for GORE(R) PROPATEN(R) Vascular Graft for Hemodialysis Access
HSMN NewsFeed - 19 Jan 2011
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
James E. Shipley, M.D., Named Chief Medical Officer of Concert Pharmaceuticals
HSMN NewsFeed - 12 Aug 2010
First Patient Implanted in Investigational Study for Self Sealing GORE(R) ACUSEAL Vascular Graft
First Patient Implanted in Investigational Study for Self Sealing GORE(R) ACUSEAL Vascular Graft
HSMN NewsFeed - 10 Aug 2010
Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development
Gregory Miller Joins Concert Pharmaceuticals as Head of Business and Corporate Development
HSMN NewsFeed - 26 Jul 2010
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
FDA Approves Tribenzor, A New Three-In-One Combination Product for the Treatment of High Blood Pressure
HSMN NewsFeed - 21 Jul 2010
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
Keryx Biopharmaceuticals, Inc. Announces Appointment of Joseph Feczko, M.D. to Board of Directors
HSMN NewsFeed - 31 Mar 2010
Abbott Submits Test to Aid in Identifying Patients at Risk of Developing Kidney Injury
Abbott Submits Test to Aid in Identifying Patients at Risk of Developing Kidney Injury
HSMN NewsFeed - 11 Mar 2010
Rex Medical Cleaner Rotational Thrombectomy System Receives 510(k) Clearance
Rex Medical Cleaner Rotational Thrombectomy System Receives 510(k) Clearance
HSMN NewsFeed - 3 Mar 2010
Solasia Pharma and Kyowa Hakko Kirin Enter Into a License Agreement for SP-01 (Sancuso) in Asia
Solasia Pharma and Kyowa Hakko Kirin Enter Into a License Agreement for SP-01 (Sancuso) in Asia
HSMN NewsFeed - 2 Mar 2010
NxStage(R) and Dirinco Sign Distribution Agreement For System One(TM) in the Netherlands
NxStage(R) and Dirinco Sign Distribution Agreement For System One(TM) in the Netherlands
HSMN NewsFeed - 3 Feb 2010
NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
NxStage(R) and Nordic Medcom Sign Distribution Agreement for the System One(TM)
HSMN NewsFeed - 1 Feb 2010
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
HSMN NewsFeed - 23 Dec 2009
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
Lilly, Kowa and Kowa Pharmaceuticals America Announce Co-Promotion and Licensing Agreement
HSMN NewsFeed - 18 Dec 2009
Xcorporeal Announces Signing Agreement for the Sale of Substantially All of Its Assets
Xcorporeal Announces Signing Agreement for the Sale of Substantially All of Its Assets
HSMN NewsFeed - 16 Sep 2009
Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
Pervasis Therapeutics Announces $17 Million in Financing and New Board Member
HSMN NewsFeed - 20 May 2009
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
HSMN NewsFeed - 23 Apr 2009
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
HSMN NewsFeed - 17 Feb 2009
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
HSMN NewsFeed - 8 Oct 2008
Xcorporeal, Inc. Appoints Kelly J. McCrann as Chairman and Chief Executive Officer
Xcorporeal, Inc. Appoints Kelly J. McCrann as Chairman and Chief Executive Officer
HSMN NewsFeed - 17 Sep 2008
Nephros Appoints Ernest A. Elgin III as President and Chief Executive Officer
Nephros Appoints Ernest A. Elgin III as President and Chief Executive Officer
HSMN NewsFeed - 12 Aug 2008
Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
HSMN NewsFeed - 22 Jul 2008
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
Santarus and Depomed Announce U.S. Promotion Agreement for GLUMETZA Prescription Products
HSMN NewsFeed - 15 Jul 2008
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
Jerini Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 21 Apr 2008
Nephros Strengthens Commercialization Team with Addition of Marketing Executive
Nephros Strengthens Commercialization Team with Addition of Marketing Executive
HSMN NewsFeed - 17 Apr 2008
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
HSMN NewsFeed - 7 Apr 2008
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
Keryx Biopharmaceuticals Announces Implementation of Strategic Restructuring Plan
HSMN NewsFeed - 24 Mar 2008
ConforMIS, Inc. Appoints Medical Device Veteran to Chief Operating Officer
ConforMIS, Inc. Appoints Medical Device Veteran to Chief Operating Officer
HSMN NewsFeed - 17 Mar 2008
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
HSMN NewsFeed - 13 Mar 2008
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
HSMN NewsFeed - 13 Feb 2008
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
HSMN NewsFeed - 11 Feb 2008
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
La Jolla Pharmaceutical Company Reports Progress in International Phase 3 Riquent(R) Study
HSMN NewsFeed - 24 Jan 2008
Ash Access Technology, Inc. Completes Patient Enrollment in AZEPTIC Trial for Zuragen(R)
Ash Access Technology, Inc. Completes Patient Enrollment in AZEPTIC Trial for Zuragen(R)
HSMN NewsFeed - 22 Jan 2008
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
Exelixis and Bristol-Myers Squibb to Co-Develop XL139, an Inhibitor of the Hedgehog Pathway
HSMN NewsFeed - 18 Jan 2008
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
HSMN NewsFeed - 17 Dec 2007
Prestigious Medical Journal Publishes Data on Xcorporeal's Wearable Artificial Kidney
Prestigious Medical Journal Publishes Data on Xcorporeal's Wearable Artificial Kidney
HSMN NewsFeed - 14 Dec 2007
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
HSMN NewsFeed - 6 Dec 2007
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
Sulodexide Data Safety Monitoring Committee Completes Additional Review of Phase 3 Study Data
HSMN NewsFeed - 20 Nov 2007
Nephros Receives Approval to Market OLpur(TM) MD Hemodiafilter Series in Canada
Nephros Receives Approval to Market OLpur(TM) MD Hemodiafilter Series in Canada
HSMN NewsFeed - 7 Nov 2007
Fresenius Medical Care Announces: Continued Positive Data from CARE-2 Database
Fresenius Medical Care Announces: Continued Positive Data from CARE-2 Database
HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
HSMN NewsFeed - 29 Oct 2007
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
Depomed and King Pharmaceuticals Terminate Promotion Agreement for GLUMETZA(TM)
HSMN NewsFeed - 29 Oct 2007
Relypsa Formed With $33 Million Series A Funding to Discover and Develop Polymeric Drugs
Relypsa Formed With $33 Million Series A Funding to Discover and Develop Polymeric Drugs
HSMN NewsFeed - 17 Oct 2007
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
FDA Approves Supplemental New Drug Applications for JANUVIA(TM) (sitagliptin)
HSMN NewsFeed - 15 Oct 2007
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM') Program from Bristol-Myers Squibb
HSMN NewsFeed - 4 Oct 2007
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
Shire's ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
HSMN NewsFeed - 24 Sep 2007
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
HSMN NewsFeed - 6 Sep 2007
Shire Appoints Anita Graham to the Newly Created Position of Chief Administrative Officer
Shire Appoints Anita Graham to the Newly Created Position of Chief Administrative Officer
HSMN NewsFeed - 13 Aug 2007
Joel Z. Melnick, MD joins Cytochroma as Vice President, Clinical & Regulatory Affairs
Joel Z. Melnick, MD joins Cytochroma as Vice President, Clinical & Regulatory Affairs
HSMN NewsFeed - 8 Aug 2007
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
Paladin Expands Distribution Agreement with Shire HGT to Include ELAPRASE(TM) (Idursulfase)
HSMN NewsFeed - 6 Aug 2007
Baxter Announces Collaboration for Development of Next-Generation Home Hemodialysis Machine
Baxter Announces Collaboration for Development of Next-Generation Home Hemodialysis Machine
HSMN NewsFeed - 17 Jul 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
HSMN NewsFeed - 17 Jul 2007
Escalon(R) Receives 510(k) Clearance from FDA for Distribution of TRILOGY(R) Analyzer
Escalon(R) Receives 510(k) Clearance from FDA for Distribution of TRILOGY(R) Analyzer
HSMN NewsFeed - 17 Jul 2007
William P. Kane Named Vice President, Commercial Operations for Keryx Biopharmaceuticals, Inc.
William P. Kane Named Vice President, Commercial Operations for Keryx Biopharmaceuticals, Inc.
HSMN NewsFeed - 29 Jun 2007
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
Shire Announces Filing of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults
HSMN NewsFeed - 14 Jun 2007
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
Shire's ELAPRASE(TM) (idursulfase) Approved by Health Canada for Treatment of Hunter Syndrome
HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
HSMN NewsFeed - 30 May 2007
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
Data Affirms Avandia (Rosiglitazone maleate) Cardiovascular Safety Profile
HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
HSMN NewsFeed - 10 May 2007
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
La Jolla Pharmaceutical Company Names Niv Caviar Chief Business and Financial Officer
HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
HSMN NewsFeed - 12 Apr 2007
Exelixis Appoints Experienced Clinician and Scientist to Vice President of Translational Medicine
Exelixis Appoints Experienced Clinician and Scientist to Vice President of Translational Medicine
HSMN NewsFeed - 11 Apr 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
HSMN NewsFeed - 10 Apr 2007
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
GTx, Inc. Appoints Jeff Hesselberg as Vice President of Regulatory Affairs
HSMN NewsFeed - 4 Apr 2007
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
GTx, Inc. Appoints Ronald A. Morton, Jr. MD, FACS as Chief Medical Officer
HSMN NewsFeed - 2 Apr 2007
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
Depomed Files Prior Approval Supplement for 1000 mg Strength Tablets of Glumetza
HSMN NewsFeed - 21 Mar 2007
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
ADDERALL XR(R) - Shire Files Suit Against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf
HSMN NewsFeed - 20 Mar 2007
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 19 Mar 2007
Angiotech Initiates U.S. Pivotal Trial for the Vascular Wrap(TM) Paclitaxel-Eluting Mesh
Angiotech Initiates U.S. Pivotal Trial for the Vascular Wrap(TM) Paclitaxel-Eluting Mesh
HSMN NewsFeed - 19 Mar 2007
Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel(TM)
Pervasis Therapeutics Launches Enrollment for Two Phase II Clinical Trials for Vascugel(TM)
HSMN NewsFeed - 12 Mar 2007
Cytochroma appoints co-founder Dr. P. Martin Petkovich as full-time Chief Scientific Officer
Cytochroma appoints co-founder Dr. P. Martin Petkovich as full-time Chief Scientific Officer
HSMN NewsFeed - 8 Mar 2007
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent(R) Lupus Phase 3 Trial
HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
HSMN NewsFeed - 20 Feb 2007
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
Shire Agrees to Acquire New River to Gain Full Control of VYVANSE(TM), its Future Flagship Product for ADHD
HSMN NewsFeed - 7 Feb 2007
NxStage(R) Medical and DaVita Announce Agreement for Home Hemodialysis Using the NxStage System One(TM)
NxStage(R) Medical and DaVita Announce Agreement for Home Hemodialysis Using the NxStage System One(TM)
HSMN NewsFeed - 2 Feb 2007
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
GTx's Phase III Clinical Development of ACAPODENE on Course Following Planned Safety Review
HSMN NewsFeed - 1 Feb 2007
Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
HSMN NewsFeed - 29 Jan 2007
Nephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application
Nephros Receives Conditional Approval from the FDA of Investigational Device Exemption Application
HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
HSMN NewsFeed - 3 Jan 2007
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
Exelixis Signs Co-Development Agreement With Genentech for Small Molecule Oncology Compound
HSMN NewsFeed - 27 Nov 2006
NxStage Medical, Inc. Appoints Robert S. Brown as Chief Financial Officer
NxStage Medical, Inc. Appoints Robert S. Brown as Chief Financial Officer
HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
HSMN NewsFeed - 6 Nov 2006
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Announces Continued Progress With Phase 3 International Riquent(R) Study
HSMN NewsFeed - 2 Nov 2006
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
Exelixis Suspends Enrollment of New Patients in XL999 Phase II Clinical Trial Program
HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
HSMN NewsFeed - 19 Oct 2006
Fresenius Medical Care Announces New Sourcing and Supply Agreement with Amgen
Fresenius Medical Care Announces New Sourcing and Supply Agreement with Amgen
HSMN NewsFeed - 16 Oct 2006
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
Neurochem submits a complete response to FDA approvable letter for KIACTA(TM)
HSMN NewsFeed - 12 Oct 2006
Fresenius Medical Care to Acquire Phosphate Binder Business from Nabi Biopharmaceuticals
Fresenius Medical Care to Acquire Phosphate Binder Business from Nabi Biopharmaceuticals
HSMN NewsFeed - 27 Sep 2006
Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review
Pervasis Therapeutics' Vascugel(TM) Initiates U.S. Clinical Trials Following Successful FDA IND Review
HSMN NewsFeed - 27 Sep 2006
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
La Jolla Pharmaceutical Provides Update on Phase 3 International Riquent(R) Study
HSMN NewsFeed - 21 Sep 2006
Ranbaxy Receives Approval to Commercialize Furosemide Tablets in the U.S.
Ranbaxy Receives Approval to Commercialize Furosemide Tablets in the U.S.
HSMN NewsFeed - 19 Sep 2006
PhytoMedical Announces Appointment of Senior Pharmaceutical Executives to Board of Directors
PhytoMedical Announces Appointment of Senior Pharmaceutical Executives to Board of Directors
HSMN NewsFeed - 28 Jun 2006
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
King Pharmaceuticals and Depomed Announce Agreement to Co-Promote Glumetza(TM)
HSMN NewsFeed - 26 Jun 2006
Exelixis Appoints Experienced Biotechnology Executive as Chief Medical Officer
Exelixis Appoints Experienced Biotechnology Executive as Chief Medical Officer
HSMN NewsFeed - 10 May 2006
NephroGenex Licenses Pyridorin(TM) for Diabetic Nephropathy and Acute Renal Failure
NephroGenex Licenses Pyridorin(TM) for Diabetic Nephropathy and Acute Renal Failure
Additional items found! 273

Members Archive contains
273 additional stories matching:
Renal Disease
(Password required)
Renal Disease
(Password required)